Skip to content

YNIOS Pharma

Active Private limited companyfounded 2022active for 4 yearsAvenue Wolfers 32, 1310 La HulpeKBO/BCE: BE 0783.494.239 subsidiary of

Annual accounts 2025

micro format, filed on 12-06-2026, 49 days before the deadline
-€4,809
▼ €397,695
-€221,902
▼ €564,993
-€228,903
▼ €571,027
-€307,374
▼ €305,964
59.6%
▼ 12.8 percentage points
0.04
▼ 0.95

The micro format does not require turnover, and these accounts state none. Without turnover there is no EBIT margin either.

Balance sheet

balance sheet total €794,459 on 31-12-2025
What the company ownsHow it is paid for

in euro

in euro

Position in the sector

59.6%

Higher than 72% of the 166 companies filing micro accounts in chemicals (NACE 20) in 2025.

0.04

Lower than 95% of the 154 companies filing micro accounts in chemicals (NACE 20) in 2025.

-28.8%

Higher than 16% of the 158 companies filing micro accounts in chemicals (NACE 20) in 2025.

YNIOS Pharma Middle half of the sector 80% of the sector Micro accounts in chemicals (NACE 20)

Net result: bottom quarter · Equity: top quarter · Balance sheet total: top quarter · Working capital: bottom quarter

Key figures and ratios

per financial year, computed from the annual accounts
Line Trend202520242023202210 months
-105,209392,499-162,217-133,939
-112,210391,532-162,991-133,977
193,754585,52197,718104,534
-252,439206,95844,314-
-307,374-1,4107,780-31,511
59.6%72.4%34.5%56.6%
0.040.991.180.43
0.680.381.890.77
-48.3%48.7%-260.1%-187.5%
-28.8%35.3%-89.8%-106.2%
-10.30over 100-209.63-2213.86

A Belgian filing has no cash-flow statement. Cash flow is therefore an approximation, derived from the income statement. Investment is the acquisitions in the notes and, without them, the balance-sheet move.

Filed annual accounts

as filed with the National Bank, click a year to choose it
Line Trend202520242023202210 months
Balance sheet: assets
20/58 794,459970,290218,657127,086
21/28 780,937703,876167,762103,502
21 780,937703,876167,762103,502
29/58 13,522266,41550,89523,584
40/41 8,1698,62366117,665
40 ---9,600
41 8,1698,6236618,065
54/58 4,753257,19250,2345,919
490/1 600600--
Balance sheet: equity and liabilities
10/49 794,459970,290218,657127,086
10/15 473,563702,46675,54271,991
10/11 691,800691,800407,000207,000
11 ---207,000
1100/10 ---207,000
14 -218,23710,666-331,458-135,009
17/49 320,896267,824143,11555,095
17 --100,000-
170/4 --100,000-
42/48 320,896267,82443,11555,095
44 2,5007,45922,79854,771
440/4 2,5007,45922,79854,771
45 3783084,372324
450/3 3783084,372324
47/48 318,019260,05715,946-
Income statement
76A -40,812--
9900 -4,809392,886-161,833-133,591
630 116,69349,40833,4581,032
640/8 400387384348
66A 100,000---
9901 -221,902343,091-195,675-134,971
75/76B -236-22
75 -236-22
65/66B 10,2171,20377461
65 10,2171,20377461
9903 -232,118342,124-196,449-135,009
67/77 -3,215---
9904 -228,903342,124-196,449-135,009
9905 -228,903342,124-196,449-135,009
Appropriation of the result
9906 -218,23710,666-331,458-135,009
14P 10,666-331,458-135,009-
Document PDFPDFPDFPDF

The full notes are in the accounts filed with the NBB.

Source: Annual accounts 2025 at the NBB, filed on 12-06-2026.

Filings

each dot is a set of accounts, on the day it reached the National Bank
Financial year Type Filed Reference Document
31-12-2025 micro format 12-06-2026 2026-00158321 PDF
31-12-2024 micro format 01-08-2025 2025-00348564 PDF
31-12-2023 micro format 02-07-2024 2024-00195250 PDF
31-12-2022 micro format 13-07-2023 2023-00238825 PDF

Investments

fixed assets acquired
Item2025202420232022
Intangible fixed assets€193,754€585,521€97,718€104,534
€116,693€49,408€33,458€1,032

Source: notes to the 2022 to 2025 annual accounts (statement of fixed assets)

Insights on YNIOS Pharma

The operating result for 2025 is a loss of €221,902, after a profit of €343,091 in 2024. It is the lowest result since 2023.

Debt's share of the balance-sheet total rises from 27.6% to 40.4%. Equity is lower and debt is higher.

Next steps